Showing results (261-270 of 286) with videos related to
Sort By:
Pageof 29
Oncogene|December 12, 2018
Cancer stem-like properties and gefitinib resistance are dependent on purine synthetic metabolism mediated by the mitochondrial enzyme MTHFD2Tatsunori Nishimura, Asuka Nakata, Xiaoxi Chen, et al.Gan to Kagaku Ryoho. Cancer & Chemotherapy|April 30, 2004
[Subset analysis of data in the Japanese patients with NSCLC from IDEAL 1 study on gefitinib]Yutaka Nishiwaki, Seiji Yano, Tomohide Tamura, et al.International Journal of Clinical Oncology|March 1, 2021
Multi-institutional survey of cancer disparities in disabled patients in the region of northwestern JapanShigeki Sato, Azusa Tanimoto, Naohiro Yanagimura, et al.Cancer Science|November 30, 2019
Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double-positive lung cancerShinji Takeuchi, Tetsunari Hase, Shinobu Shimizu, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2003
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]Masahiro Fukuoka, Seiji Yano, Giuseppe Giaccone, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2023
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non-Small-Cell Lung CancerMasahiro Fukuoka, Seiji Yano, Giuseppe Giaccone, et al.Journal of Immunology (Baltimore, Md. : 1950)|May 22, 2013
A novel targeting therapy of malignant mesothelioma using anti-podoplanin antibodyShinji Abe, Yuki Morita, Mika Kato Kaneko, et al.Lung Cancer (Amsterdam, Netherlands)|November 22, 2021
A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancerHiroyuki Yasuda, Eiki Ichihara, Jun Sakakibara-Konishi, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 5, 2011
Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohortSeiji Yano, Tadaaki Yamada, Shinji Takeuchi, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 19, 2020
ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non-Small Cell Lung CancerNaoko Okura, Naoya Nishioka, Tadaaki Yamada, et al.Pageof 29